Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.9500 |
Strike | 15.00 |
Expiry date | 2025-01-17 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 819 |
Key Insights Given the large stake in the stock by institutions, uniQure's stock price might be vulnerable to their...
Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company. Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure's clinical portfolio and CSL's commercial HEMGENIX® product, the first one-time gene therapy approved in the U.S. and Europe for the treatment o
~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global commercial supply of HEMGENIX® and support uniQure’s pipeline programs as a preferred customer ~ ~ uniQure to reduce cash burn by $40 million per year and receive total consideration of $25 million ~ ~ uniQure’s comprehensive review of operations and options to reduce expenses is ongoing and expected to be comp